Posted by Michael Wonder on 24 Jan 2017
Roche says FDA grants priority review for Actemra
24 January 2017 - The U.S. FDA has granted priority review designation of Roche's rheumatoid arthritis medication Actemra for giant cell arteritis, the Swiss drug maker said on Tuesday.
"We will continue to work closely with the FDA to bring this investigational medicine to people with giant cell arteritis as quickly as possible," Sandra Horning, Roche's chief medical officer and head of global product development, said in a statement.
Giant cell arteritis is a chronic, potentially life-threatening auto-immune condition caused by inflammation of large and medium-sized arteries, most often in the head but also in the aorta and its branches.
